A bigger BioMarin faces pipeline setbacks and heavy debt
- BioMarin bought Amicus in April 2026 for about $4.8 billion, adding Galafold and Pombiliti + Opfolda.
- The deal makes BioMarin less dependent on Voxzogo, but total debt rose to about $4.3 billion.
- In August 2026, the company stopped development of BMN 401 after a trial failure.
- Voxzogo remains the core growth engine, with a key FDA decision set for February 2027.
- The stock story is balanced: more products and cash flow, but more integration risk and interest expense.
Diversification with a bill attached
BioMarin has changed shape. The Amicus deal closed in April 2026, adding Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease. That gives BioMarin more commercial products and less reliance on Voxzogo alone.
The bull case is simple. If BioMarin keeps growing Voxzogo, folds in Amicus without losing talent or sales momentum, and uses cash flow to pay down debt, the company could become a larger rare disease leader with better earnings power.
The bear case centers on execution and debt. Total debt rose to about $4.3 billion after the close, and interest expense is set to rise. Furthermore, pipeline failures like the August 2026 discontinuation of BMN 401 highlight the risks of drug development.
The next year is about proof. Investors need to see Galafold and Pombiliti + Opfolda reported clearly, debt moving down, Voxzogo still growing, and successful integration of new assets like BMN 820.
Rare diseases, high prices, small markets
BioMarin sells medicines for rare genetic diseases. These patient groups are small, so the company needs high per-patient prices and broad access to doctors, hospitals, insurers, and government buyers.
The model can work well when a drug becomes the main treatment for a serious disease. Voxzogo, Vimizim, Naglazyme, and other enzyme therapies have built a real commercial base. Q1 2026 net product revenue was $760.1 million.
The Amicus acquisition broadens that base, but it also changes the risk. BioMarin now has more products to sell, more teams to combine, more manufacturing complexity, and more debt to service.
Manufacturing matters. In Q1 2026, BioMarin recorded a $31.0 million charge tied to an unsuccessful Naglazyme manufacturing campaign. For a rare disease company, one failed production run can hit margins.
The drugs that drive the story
Voxzogo
Voxzogo treats achondroplasia and was BioMarin's largest product in Q1 2026 at $219.9 million. It faces a key FDA approval decision in February 2027.
Vimizim
Vimizim treats MPS IVA and produced $210.2 million of Q1 2026 net product revenue. It is part of the enzyme therapy base that helps fund the pipeline.
Naglazyme
Naglazyme treats MPS VI and produced $130.1 million in Q1 2026. The recent manufacturing charge shows that even established products can create cost surprises.
Galafold and Pombiliti + Opfolda
These Amicus products were added after the April 2026 deal closed. They bring commercial exposure to Fabry disease and late-onset Pompe disease.
Palynziq
Palynziq treats PKU and produced $89.6 million in Q1 2026. In February 2026, the FDA approved it for adolescents 12 years of age and older with PKU.
BMN 820
BioMarin acquired U.S. rights to BMN 820 in April 2026. It is an oral inhibitor targeting focal segmental glomerulosclerosis.
BMN 333 and BMN 351
BMN 333 is a long-acting CNP program for achondroplasia, and BMN 351 targets Duchenne muscular dystrophy. These are future bets, not current profit drivers.
Q1 mix before Amicus
This mix uses Q1 2026 net product revenue from the March 31, 2026 10-Q. It does not include Galafold or Pombiliti + Opfolda, because Amicus closed after quarter-end.
What could go wrong
Amicus integration misses the plan
High impact · Medium oddsBioMarin is combining a large acquired business after paying about $4.8 billion. If it cannot keep key people, keep customers, and cut costs without hurting sales, the deal could destroy value instead of adding it.
Debt limits flexibility
High impact · Medium oddsTotal debt rose to about $4.3 billion after the Amicus close. Higher interest expense can reduce cash available for research, launches, and future deals.
Pipeline setbacks hurt growth
High impact · Medium oddsThe failure of the BMN 401 trial in August 2026 shows the danger of relying on clinical readouts. Setbacks in the remaining pipeline place even more pressure on the commercial business.
Manufacturing problems hit margins
Medium impact · Medium oddsRare disease drugs can be hard to make, and supply is often tied to a small number of facilities. The $31.0 million Naglazyme charge in Q1 2026 is a clear example of how production problems can hurt gross margin.
Pricing pressure rises
Medium impact · Medium oddsBioMarin depends on high per-patient pricing because its diseases have small patient groups. Government price controls, payer pushback, or new competitors could weaken that model.
In one breath
What does BioMarin do?
BioMarin develops and sells medicines for rare genetic diseases. Its main commercial products include Voxzogo, Vimizim, Naglazyme, Palynziq, Aldurazyme, Brineura, and the newly acquired Amicus products.
Why did BioMarin buy Amicus?
The deal adds Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease. It diversifies BioMarin's revenue, but it also added a large debt load.
Is Voxzogo still important?
Yes. Voxzogo produced $219.9 million in Q1 2026 and remains the main internal growth driver. An FDA decision on expanding approval is expected in February 2027.
What is the biggest risk for BMRN now?
The biggest risk is execution after the Amicus acquisition. BioMarin must integrate the business, report strong sales from the acquired products, and reduce debt while managing pipeline setbacks.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 16, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near BioMarin Pharmaceutical Inc. in Finn's Biotechnology industry ranking.
